A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With R... by Beckermann, Kathryn E., MD, PhD, Bestvina, Christine M., MD, El Osta, Badi, MD, Sanborn, Rachel E., MD, Borghaei, Hossein, MD, Lammers, Philip Edward, MD, MSCI, Selvaggi, Giovanni, MD, Whisenant, Jennifer G., PhD, Heimann-Nichols, Ellen, MBA, Berry, Lynne, PhD, Hsu, Chih-Yuan, PhD, Shyr, Yu, PhD, Horn, Leora, MD, MSc, MHPE, Wakelee, Heather, MD, FASCO

Get full text

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study by Antonia, Scott, Prof, Goldberg, Sarah B, MD, Balmanoukian, Ani, MD, Chaft, Jamie E, MD, Sanborn, Rachel E, MD, Gupta, Ashok, MD, Narwal, Rajesh, PhD, Steele, Keith, PhD, Gu, Yu, PhD, Karakunnel, Joyson J, MD, Rizvi, Naiyer A, Prof

Get full text

Results of Lung Cancer Screening in the Community by Handy, John R., MD, Skokan, Michael, MD, Rauch, Erika, MA, Zinck, Steven, MD, Sanborn, Rachel E., MD, Kotova, Svetlana, MD, Wang, Mansen, PhD

Get full text

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, s... by Rizvi, Naiyer A, Dr, Mazières, Julien, Prof, Planchard, David, MD, Stinchcombe, Thomas E, MD, Dy, Grace K, MD, Antonia, Scott J, MD, Horn, Leora, MD, Lena, Hervé, MD, Minenza, Elisa, MD, Mennecier, Bertrand, MD, Otterson, Gregory A, MD, Campos, Luis T, MD, Gandara, David R, MD, Levy, Benjamin P, MD, Nair, Suresh G, MD, Zalcman, Gérard, Prof, Wolf, Jürgen, Prof, Souquet, Pierre-Jean, MD, Baldini, Editta, MD, Cappuzzo, Federico, MD, Chouaid, Christos, MD, Dowlati, Afshin, MD, Sanborn, Rachel, MD, Lopez-Chavez, Ariel, MD, Grohe, Christian, Prof, Huber, Rudolf M, Prof, Harbison, Christopher T, PhD, Baudelet, Christine, PhD, Lestini, Brian J, MD, Ramalingam, Suresh S, Prof

Get full text